Understanding tendon-bone attachment issues in a mouse model of X-linked hypophosphatemia
Development of enthesopathy in the mouse model of X-linked hypophosphatemia
This study is looking at how a painful condition called enthesopathy develops in mice with a genetic disorder that affects bone health, and it aims to find out if certain treatments can help prevent this issue, which could lead to better care for people with the same condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11007193 on NIH RePORTER |
What this research studies
This research investigates the development of enthesopathy, a painful condition affecting the tendon-bone attachment sites, in a mouse model of X-linked hypophosphatemia (XLH). The study focuses on how mutations in the PHEX gene lead to elevated levels of FGF23, resulting in low phosphate levels and impaired vitamin D production. By examining the effects of treatments like 1,25D and FGF23 blocking antibodies, the researchers aim to uncover the mechanisms behind enthesopathy and identify potential early interventions to prevent this debilitating condition. Patients may benefit from insights gained about the timing and effectiveness of treatments for XLH-related complications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with X-linked hypophosphatemia, particularly those experiencing symptoms related to enthesopathy.
Not a fit: Patients without X-linked hypophosphatemia or those who do not exhibit enthesopathy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for preventing painful tendon-bone attachment issues in patients with X-linked hypophosphatemia.
How similar studies have performed: While the specific approach in this research is novel, previous studies have shown that targeting FGF23 can have beneficial effects in related conditions.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Liu, Eva S. — Brigham and Women's Hospital
- Study coordinator: Liu, Eva S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.